As the WHO de­clared the mon­key­pox out­break to be a glob­al health emer­gency, Bavar­i­an Nordic ob­tained an ex­pand­ed Eu­ro­pean la­bel for its small­pox vac­cine to in­clude the surg­ing virus.

The move comes rough­ly a month af­ter the biotech filed for a la­bel ex­pan­sion, and af­ter sev­er­al coun­tries on the con­ti­nent, and else­where, se­cured their own sup­ply deals for the shot. Bavar­i­an Nordic has said it’s seen “over­whelm­ing” in­ter­est in the vac­cine, and its stock price $BVRNY has fol­lowed in short or­der — shares are up 124% since the first mon­key­pox case was de­tect­ed on May 6.

Mon­day’s ap­proval will like­ly help boost sup­ply of the vac­cine across Eu­rope just a few days af­ter the WHO raised the mon­key­pox alert lev­el to its high­est clas­si­fi­ca­tion Sat­ur­day, of­fi­cial­ly de­clar­ing the out­break a glob­al health emer­gency. There had been more than 17,000 cas­es around the world as of Sat­ur­day, rough­ly a 50% in­crease over the last week, with cas­es in over 75 coun­tries.

“WHO’s as­sess­ment is that the risk of mon­key­pox is mod­er­ate glob­al­ly and in all re­gions, ex­cept in the Eu­ro­pean re­gion where we as­sess the risk as high,” WHO di­rec­tor-gen­er­al Tedros Ad­hanom Ghe­breye­sus said in a state­ment Sat­ur­day. “There is al­so a clear risk of fur­ther in­ter­na­tion­al spread, al­though the risk of in­ter­fer­ence with in­ter­na­tion­al traf­fic re­mains low for the mo­ment.”

The de­c­la­ra­tion was a re­ver­sal from WHO’s pre­vi­ous stance a month ago, when the WHO de­clined to el­e­vate the out­break’s sta­tus.

Last week, Eu­rope se­cured an­oth­er sup­ply deal for Bavar­i­an Nordic’s shot, or­der­ing 54,000 dos­es to bring its to­tal stash to 160,000. An ini­tial or­der of 110,000 shots came in late June, pro­vid­ing more ac­cess to the vac­cine on the con­ti­nent where in­di­vid­u­als had strug­gled to get it.

Oth­er coun­tries, too, have been or­der­ing the jab. Cana­da signed a $56 mil­lion con­tract last month and Bavar­i­an Nordic has pre­vi­ous­ly said it’s been in dis­cus­sions with coun­tries in Asia, Eu­rope, South Amer­i­ca and the Mid­dle East as well.

BAR­DA, mean­while, bought 2.5 mil­lion dos­es for the US na­tion­al stock­pile ear­li­er this month, and has said it ex­pects to de­liv­er 1.6 mil­lion dos­es by the end of the year.

Rising monkeypox cases have put the US on high alert as it announces a national health emergency, which grants the government more power in its response.

The news comes as Bavarian Nordic continues to fill orders for its Jynneos vaccine and other companies – including Moderna – consider jumping into the vaccine race. Meanwhile, the New York Times reports that the US has allowed around 20 million doses of smallpox vaccine in its stockpile to expire.

Forget buyer’s remorse, Pfizer is likely feeling pretty good about its $11.6 billion Biohaven takeover deal following reports of a 57% sales boost for migraine med Nurtec.

Biohaven reported in Q2 results on Friday that it’s cleared the necessary antitrust hurdles to move forward with the sale of its calcitonin gene-related peptide (CGRP) assets to Pfizer. However, because the company is “focused on workstreams related to the closing” of the deal, it did not host a call with analysts and investors.